# reload+after+2024-01-22 15:45:26.743577
address1§11025 North Torrey Pines Road
address2§Suite 200 Torrey Pines Science Park
city§La Jolla
state§CA
zip§92037
country§United States
phone§858 795 4220
website§https://inhibrx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.
fullTimeEmployees§132
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Mark Paul Lappe', 'age': 56, 'title': 'Founder, Chairman, President & CEO', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 1022750, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Brendan P. Eckelman Ph.D.', 'age': 44, 'title': 'Founder & Chief Scientific Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 704000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kelly Devine Deck B.S., CPA, M.S.', 'age': 42, 'title': 'Executive VP & CFO', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 531168, 'exercisedValue': 0, 'unexercisedValue': 1445398}, {'maxAge': 1, 'name': 'Mr. Quinn L. Deveraux', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ashraf  Amanullah', 'age': 55, 'title': 'Executive VP & Chief Technical Operations Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Leah  Pollema J.D.', 'title': 'VP, Corporate Secretary & General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Charbel  Helaihel Pharm.D.', 'title': 'Vice President of Marketing & Commercial Planning', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeffrey J. Jensen', 'title': 'Executive VP & Chief Clinical Operations Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Matly M.B.A.', 'title': 'Executive VP and Chief Commercial & Business Development Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Carlos  Bais Ph.D.', 'title': 'Executive Vice President of Translational Sciences', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§9
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§3.037
priceToSalesTrailing12Months§3813.35
currency§USD
dateShortInterest§1702598400
forwardEps§-4.12
exchange§NGM
quoteType§EQUITY
shortName§Inhibrx, Inc.
longName§Inhibrx, Inc.
firstTradeDateEpochUtc§1597843800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§65117bf8-50e3-3c16-a5dd-bee97e3c0678
gmtOffSetMilliseconds§-18000000
targetHighPrice§60.0
targetLowPrice§27.0
targetMeanPrice§44.25
targetMedianPrice§45.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§9.439
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
